Update: J&J COVID vaccine rollout paused as clot concerns spreadUS health authorities have recommended pausing dosing with Johnson & Johnson’s COVID-19 vaccine as they investigate cases of Share XUpdate: J&J COVID vaccine rollout paused as clot concerns spreadhttps://pharmaphorum.com/news/us-seeks-halt-on-jj-covid-vaccine-rollout-as-clot-concerns-spread/
England begins Moderna vaccine rollout as lockdown easesEngland is beginning its rollout of the Moderna COVID-19 vaccine, offering an alternative to the AstraZeneca/Oxford University jab Share XEngland begins Moderna vaccine rollout as lockdown easeshttps://pharmaphorum.com/news/england-begins-moderna-vaccine-rollout-as-lockdown-eases/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialAntios has raised $96 million in Series B financing to support the ongoing phase 2 development of its Share XRace for hepatitis B drug intensifies as Antios raises $96m for phase 2 trialhttps://pharmaphorum.com/news/race-for-hepatitis-b-drug-intensifies-as-antios-raises-96m-for-phase-2-trial/
Akari begins late-stage trial of nomacopan for Bullous PemphigoidAkari Therapeutics is to begin a late-stage trial of nomacopan, its potential therapy for Bullous Pemphigoid, the rare Share XAkari begins late-stage trial of nomacopan for Bullous Pemphigoidhttps://pharmaphorum.com/news/akari-begins-late-stage-trial-of-nomacopan-for-bullous-pemphigoid/
Apple, Google block NHS contact tracing app update on privacy groundsA scheduled update to the NHS COVID-19 app has been blocked because it allows location tracking – something Share XApple, Google block NHS contact tracing app update on privacy groundshttps://pharmaphorum.com/news/apple-google-block-nhs-contact-tracing-app-update-on-privacy-grounds/
Fishawack buys health economics consultancy PRMAUK comms agency Fishawack Health has acquired the health economics outcomes research (HEOR) consultancy PRMA Consulting. PRMA has Share XFishawack buys health economics consultancy PRMAhttps://pharmaphorum.com/news/fishawack-buys-health-economics-consultancy-prma/
South African variant may evade Pfizer/BioNTech vaccine, study findsThe coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted Share XSouth African variant may evade Pfizer/BioNTech vaccine, study findshttps://pharmaphorum.com/news/south-african-variant-may-evade-pfizer-biontech-vaccine-study-finds/
Regeneron’s antibody cocktail hits target in COVID prevention studyRegeneron is to ask the FDA for clearance to use its antibody cocktail as a preventive treatment for Share XRegeneron’s antibody cocktail hits target in COVID prevention studyhttps://pharmaphorum.com/news/regeneron-to-ask-fda-to-c/
AstraZeneca’s Farxiga fails phase 3 COVID-19 testHope that AstraZeneca’s diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed Share XAstraZeneca’s Farxiga fails phase 3 COVID-19 testhttps://pharmaphorum.com/news/astrazenecas-farxiga-fails-phase-3-covid-19-test/
Sanofi licences in potential oral IL-17 drug from UK’s C4X DiscoverySanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal Share XSanofi licences in potential oral IL-17 drug from UK’s C4X Discoveryhttps://pharmaphorum.com/news/sanofi-licences-in-potential-oral-il-17-drug-from-uks-c4x-discovery/
Exscientia starts trials of first AI-derived cancer immunotherapyExscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) Share XExscientia starts trials of first AI-derived cancer immunotherapyhttps://pharmaphorum.com/news/exscientia-starts-trials-of-first-ai-derived-cancer-immunotherapy/
Merck’s Keytruda demonstrates adjuvant use in kidney cancerMerck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for Share XMerck’s Keytruda demonstrates adjuvant use in kidney cancerhttps://pharmaphorum.com/news/mercks-keytruda/
Provention faces delay in FDA review of diabetes prevention antibodyThe FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for Share XProvention faces delay in FDA review of diabetes prevention antibodyhttps://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/
Lilly’s Olumiant flunks COVID-19 trial – or does it?Eli Lilly’s JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 Share XLilly’s Olumiant flunks COVID-19 trial – or does it?https://pharmaphorum.com/news/lillys-olumiant-flunks-covid-19-trial-or-does-it/
Healx deploys its AI in hunt for Friedreich’s ataxia therapiesUK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new Share XHealx deploys its AI in hunt for Friedreich’s ataxia therapieshttps://pharmaphorum.com/news/healx-deploys-its-ai-in-hunt-for-friedreichs-ataxia-therapies/
Digital tool will be tested against COVID-19 ‘brain fog’A digital tool used to treat attention-deficit hyperactivity disorder (ADHD) is being tested to see if it can Share XDigital tool will be tested against COVID-19 ‘brain fog’https://pharmaphorum.com/news/digital-tool-will-be-tested-against-covid-19-brain-fog/
Cancer Research UK spinout Achilles raises $175.5m in IPOUK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that Share XCancer Research UK spinout Achilles raises $175.5m in IPOhttps://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/
KOL Mindset Mapping Share XKOL Mindset Mappinghttps://pharmaphorum.com/partner-content/kol-mindset-mapping/
J+D Forecasting provides Online Team Pharma Forecasting Training Share XJ+D Forecasting provides Online Team Pharma Forecasting Traininghttps://pharmaphorum.com/partner-content/jd-forecasting-provides-online-team-pharma-forecasting-training/
Continuity of Care in a Pandemic: Reflecting on the Rise of Telehealth Share XContinuity of Care in a Pandemic: Reflecting on the Rise of Telehealthhttps://pharmaphorum.com/partner-content/continuity-of-care-in-a-pandemic-reflecting-on-the-rise-of-telehealth/
Prescient Healthcare Group to Partner with Bridgepoint Development Capital Share XPrescient Healthcare Group to Partner with Bridgepoint Development Capitalhttps://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/
Prescient Announces Recent Appointments to its Senior Team Share XPrescient Announces Recent Appointments to its Senior Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-its-senior-team/
